Ultragenyx Pharmaceutical Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2012 | $-12.5M | $-13.6M | $1.1M | $891.0K |
| FY2013 | $-31.2M | $-31.6M | $407.0K | $657.0K |
| FY2014 | $-44.6M | $-46.8M | $2.1M | $5.4M |
| FY2015 | $-106.0M | $-110.9M | $5.0M | $24.9M |
| FY2016 | $-161.0M | $-171.2M | $10.2M | $48.3M |
| FY2017 | $-253.8M | $-256.6M | $2.8M | $68.0M |
| FY2018 | $-290.6M | $-294.6M | $4.1M | — |
| FY2019 | $-345.4M | $-370.2M | $24.8M | — |
| FY2020 | $-132.2M | $-176.1M | $43.9M | — |
| FY2021 | $-338.7M | $-411.8M | $73.1M | — |
| FY2022 | $-380.5M | $-496.6M | $116.1M | — |
| FY2023 | $-475.0M | $-519.0M | $44.0M | — |
| FY2024 | $-414.0M | $-421.0M | $7.0M | — |
| FY2025 | $-466.0M | $-472.0M | $6.0M | — |